Clinical trial • Phase II • Immunology
Q702 for Chronic graft-versus-host disease
Phase II trial of Q702 for Chronic graft-versus-host disease. 16 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Chronic graft-versus-host disease
- Trial Stage
- Phase II
Key dates
- Initial CTIS Submission Date
- 29-07-2025
- First CTIS Authorization Date
- 24-11-2025
Trial design
Phase II trial across 10 sites in Spain.
- Target Sample Size
- 16
Eligibility
Recruits 16 Vulnerable population selected; no details on consent or assent handling provided in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent handling provided in the record.
Recruitment
- Planned Sample Size
- 16
- Recruitment Window Months
- 39
- Consent Approach
- No details on informed consent or assent provided; vulnerable population selected.
Geography
- Total Number Of Sites
- 10
- Total Number Of Participants
- 16
Spain
- Earliest CTIS Part Ii Submission Date
- 07-11-2025
- Latest Decision Or Authorization Date
- 19-01-2026
- Processing Time Days
- 73
- Number Of Sites
- 10
- Number Of Participants
- 16
Sites
- Site Name
- Hospital Universitario Y Politecnico La Fe
- Department Name
- Hematology
- Contact Person Name
- Jaime Sanz Caballer
- Contact Person Email
- sanz_jai@gva.es
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Hematology
- Contact Person Name
- Carmen Martinez Munoz
- Contact Person Email
- CMARTI@clinic.cat
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- Hematology
- Contact Person Name
- Jose Antonio Perez Simon
- Contact Person Email
- josea.perez.simon.sspa@juntadeandalucia.es
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Hematology
- Contact Person Name
- Sara Villar Fernandez
- Contact Person Email
- svillar@unav.es
- Site Name
- Hospital Universitario Puerta De Hierro De Majadahonda
- Department Name
- Hematology
- Contact Person Name
- Rafael Francisco Duarte Palomino
- Contact Person Email
- rafael.duarte@uam.es
- Site Name
- Hospital Universitario Marques De Valdecilla
- Department Name
- Hematology
- Contact Person Name
- Maria Aranzazu Bermudez Rodriguez
- Contact Person Email
- maria.bermudez@scsalud.es
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Hematology
- Contact Person Name
- Jose Luis Pinana Sanchez
- Contact Person Email
- pinana_jos@gva.es
- Site Name
- Hospital General Universitario Gregorio Maranon
- Department Name
- Hematology
- Contact Person Name
- Mi Kwon
- Contact Person Email
- mi.kwon@salud.madrid.org
- Site Name
- University Clinical Hospital Virgen De La Arrixaca
- Department Name
- Hematology
- Contact Person Name
- Andres Sanchez Salinas
- Contact Person Email
- andres.sanchez3@carm.es
- Site Name
- Hospital Universitario Regional De Malaga
- Department Name
- Hematology
- Contact Person Name
- Maria Jesus Pascual Cascon
- Contact Person Email
- mariaj.pascual.sspa@juntadeandalucia.es
Sponsor
Primary sponsor
- Full Name
- Qurient Co. Ltd.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Korea, Republic of
Investigational products
- Investigational Product Name
- Q702
Related trials
Other published trials that may interest you.
- CD19 CAR T cells (autologous) for Chronic graft-versus-host disease
- AXATILIMAB for Chronic graft-versus-host disease
- AXATILIMAB for Chronic graft-versus-host disease
- AXATILIMAB for Chronic graft-versus-host disease
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)